Article

Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling

2024-09-28

Abstract excerpt

Non-small cell lung cancers (NSCLC) harboring common mutations in EGFR and KRAS characteristically respond transiently to targeted therapies against those mutations, but invariably, tumors recur and progress. Resistance often emerges through mutations in the therapeutic target or activation of alternative signaling pathways. Mechanisms of acute tumor cell resistance to initial EGFR (EGFRi) or KRAS G12C (G12Ci) pa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 40242937-82fa-5316-bbde-e8484be218bd
DOI: 10.1101/2024.09.26.615226

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP SignalingDOI 10.1101/2024.09.26.615226Read

CRISPR Screens Reveal YAP/TEAD Axis as a Mediator of Drug-Tolerant Cells in EGFR- Mutant NSCLCSemantic proximity Read

Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.Semantic proximity Read

Complementary modes of resistance to <i>EGFR</i> TKI in lung adenocarcinoma through MAPK activation and cellular plasticitySemantic proximity Read

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinomaSemantic proximity Read

CRISPR screens reveal YAP/TEAD axis as a mediator of drug-tolerant cells in EGFR-mutant NSCLC.Semantic proximity Read

Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.Semantic proximity Read

Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbationsSemantic proximity Read

Activation of NF-κB/ALDH1A1 Signaling Promotes Non-Mutational Resistance to EGFR-TKIs in Non-Small Cell Lung CancerSemantic proximity Read

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in <i>EGFR</i> -mutant NSCLCSemantic proximity Read

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapiesSemantic proximity Read

Potentiation of EGFR mutant lung cancer treatment targeting replication stressSemantic proximity Read

Signaling networks assembled by oncogenic EGFR and c-MetSemantic proximity Read